Get the Stockscreener App
3.56
14.22%
-0.59
After Hours:
3.60
0.04
+1.12%
Zentalis Pharmaceuticals Inc stock is traded at $3.56, with a volume of 4.58M.
It is down -14.22% in the last 24 hours and down -25.37% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.15
Open:
$3.53
24h Volume:
4.58M
Relative Volume:
3.79
Market Cap:
$255.15M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-2.0486
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
-15.64%
1M Performance:
-25.37%
6M Performance:
+48.95%
1Y Performance:
+140.54%
1-Day Range:
$3.49
$3.70
1-Week Range:
$3.49
$4.42
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.56 | 307.47M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals stock falls on public offering news By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals stock falls on public offering news - Investing.com
HC Wainwright Analysts Decrease Earnings Estimates for ZNTL - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Raises Target Price to $5 - Moomoo
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Highlights Q2 Results and Azenosertib Progress - The Globe and Mail
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingView
Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results - MarketBeat
ZNTL Advances Clinical Trials for Ovarian Cancer Drug Amid Valua - GuruFocus
Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Zentalis Q2 FY26 net loss widens to $42.29 million - Bitget
ZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingView
BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BlackRock (NYSE: BLK) discloses 5.2% ownership in Zentalis Pharmaceuticals (ZNTL) - Stock Titan
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
TradingKey - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055 - TradingKey
ZNTL Initiated Coverage by Rodman & Renshaw -- Price Target Anno - GuruFocus
Rodman & Renshaw initiates Zentalis stock with buy on drug potential - Investing.com Canada
Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
Weekly Recap: DENALI Part 1b azenosertib OS data and Mizuho Outperform $8 - TradingView
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
Zentalis Pharmaceuticals Surges 11.8%: Key Levels and Potential CatalystsCounter Trend Trade - dars.gov.et
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL) - The Globe and Mail
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo
Mizuho Securities Initiates Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Announces Target Price $8 - Moomoo
Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):